You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
印度疫情持續失控 中國疫苗股國藥(01099.HK)復星醫藥(02196.HK)逆市續漲逾8.5%-13%破頂
阿思達克 05-03 13:59
印度新冠疫情持續失控,反觀中國疫苗受到更多國家認可。相關股疫情股逆市續漲,尤其是復星醫藥(02196.HK)四連漲屢探頂,今天股價更突破2018年3月所創紀錄高位54.4元後,午後升幅擴大至13.5%,報56元,成交仍有1,183萬股。國藥(01099.HK)股價也升破上周所創52周高位24.8元,最高見26.5元,現造26.2元,續升8.7%,成交增至1,668萬股。

不過,已七連升的康希諾生物-B(06185.HK)今早股價平開,曾升至394.6元,暫受制今年2月所創紀錄高位,掉頭回吐低見380元,現造383.2元,回吐1.5%。

印度疫情持續惡化,新增單日確診病例36.81萬宗,連續第12天單日新增確診人數超過30萬宗。世衛警告,印度疫情危機可能會「發生在任何地方」。事實上,中國部分城市已檢出印度變異毒株,香港也出現首例本地感染南非變種病毒,更多國家開始批准中國疫苗,最新是印尼批准使用國藥疫苗,埃及和孟加拉近日也剛批准科興和國藥疫苗。此外,世衛可能於兩周內認證中國疫苗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account